Evidence map›Paper›PMID 39497310›Full record

ArticleJournal of Alzheimer's disease : JAD2024

Association between selective serotonin reuptake inhibitors and mortality following COVID-19 among patients with Alzheimer's disease.

Zhenxiang Gao, Ian Dorney, Pamela B Davis, David C Kaelber, Rong Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhenxiang GaoCenter for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Ian DorneyCenter for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Pamela B DavisCenter for Community Health Integration, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
David C KaelberCenter for Clinical Informatics Research and Education, The Metro Health System, Cleveland, OH, USA.
Rong XuCenter for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Funding

Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)UM1TR004528 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI GRACE A MCCOMSEY · 2023 to 2026
$32.1M
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's DiseaseR01AG061388 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI CHEN, SHU G., XU, RONG · 2018 to 2022
$3.4M
An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's DiseaseR01AG057557 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2017 to 2021
$2.8M
Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatmentsRF1AG076649 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B, XU, RONG · 2022 to 2022
$2.3M
Construct large-scale phenomes of disease and drugs and develop data-driven systems approaches to understand genetic links between Alzheimer's disease and Neuropsychiatric symptomsR56AG062272 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2018 to 2019
$1.6M
Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatmentsR01AG076649 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI Rong Xu · 2025 to 2026
$1.6M
Characterize multifaceted interactions between COVID-19 and alcohol use disorder based on real-time analysis of electronic health records of 62 million adult patientsR01AA029831 · NIAAA · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B, XU, RONG · 2021 to 2023
$1.1M
NCATS NIH HHS UM1 TR004528NIAAA NIH HHS R01 AA029831NIA NIH HHS R01 AG057557NIA NIH HHS R01 AG061388NIA NIH HHS R01 AG076649NIA NIH HHS R56 AG062272NIA NIH HHS RF1 AG076649
6 · The paper itself

Abstract

backgroundRecent research suggests that selective serotonin reuptake inhibitors (SSRIs) may reduce mortality in COVID-19 patients; however, research into their benefits for elderly Alzheimer's disease (AD) patients remains limited.

objectiveTo investigate the relationship between SSRIs therapy and the mortality risk after COVID-19 infection in elderly patients with and without AD.

methodsThis retrospective cohort study leveraged a large database containing over 100 million electronic health records in the US from the TriNetX platform to compare the hazard rates of mortality after COVID-19 infection in elderly AD patients prescribed SSRIs versus propensity-score matched individuals prescribed other antidepressants. This study was also conducted in separate cohorts of patients without AD to compare the findings.

resultsWhen compared with non-SSRI antidepressants, SSRIs were associated with lower risk for mortality after COVID-19 infection in elderly patients without AD over early, middle, and later stages of the pandemic with HRs of 0.84 (95% CI: 0.75-0.93), 0.86 (95% CI: 0.79-0.93), and 0.77 (95% CI: 0.71-0.33), respectively. When comparing SSRIs with non-SSRI antidepressants for mortality risk following COVID-19 among patients with AD, HRs of 0.95 (95% CI: 0.71-1.27), 0.80 (95% CI: 0.61-1.06), and 0.99 (95% CI: 0.75-1.32), were found respectively.

conclusionsOur findings suggest that the use of SSRIs is significantly associated with reduced mortality risk following COVID-19 in elderly patients without AD compared to other antidepressants. While a lower mortality risk was also observed among AD patients, the association was not statistically significant.

Indexed as

Alzheimer DiseaseCOVID-19Selective Serotonin Reuptake InhibitorsAgedAged, 80 and overAntidepressive AgentsFemaleHumansMaleRetrospective StudiesUnited StatesAntidepressive AgentsSelective Serotonin Reuptake InhibitorsAlzheimer's diseaseCOVID-19mortalityselective serotonin reuptake inhibitors

Identifiers

PMID39497310
PMCPMC12365858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.